Skip to Main Content

Paper Details

PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Cancer Discov
192
2017
Alveolar rhabdomyosarcoma, BET, BET Bromodomain, BET bromodomain protein, BET bromodomains, BRD, BRD4, FOXO1, MYCN, MYOD, MYOG, Myogenic Super Enhancers, PAX-fusion, PAX-fusion rhabdomyosarcoma, PAX3, PAX3-FOXO1-occupied super enhancers, cell lines, children, chromatin, cis, myoblastic super enhancer landscape, myogenic cancer, myogenic super enhancer circuitry, patients, pediatric fusion-positive rhabdomyosarcoma, primary tumors, super enhancers
Author NameAffiliation
Xiaohu ZhangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Young K Song
Young K Song
Jun S Wei
Jun S Wei
Frederic G Barr
Frederic G Barr
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Marc FerrerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Jack F Shern
Jack F ShernCenter for Cancer Research
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Javed Khan
Javed Khan
  • 1 - 15

Datasets

Release 1.2